GFAP and central nervous system cancer: In our previous work, we have undertaken the task of using new technology, the proximity extension assay (PEA) [23], to quantitatively profile for the first time ~ 3,000 proteins in plasma of glioma and other brain malignancies to confirm (GFAP, NEFL) and discover additional glioma biomarkers, which, individually or as a small panel, could assist in glioma patient management [24].